Brookfield Corporation's Core Earnings Compound at 13% While the Stock Trades Like a Levered Bond
The alternative-manager complex re-rated together, and Brookfield, with the longest-duration assets of the group, absorbed more of it.
Read Article ›The alternative-manager complex re-rated together, and Brookfield, with the longest-duration assets of the group, absorbed more of it.
Read Article ›At under seven times forward earnings, with the share count structurally shrinking and a third-quarter consensus that requires a collapse four quarters of cash receipts contradict, the stock is mispriced to the upside, and the November print is the most likely thing to correct...
Read Article ›The market repriced the whole company for a disruption thesis about Legal; yet Legal supplies roughly an eighth of group profit and it is the division that sped up.
Read Article ›A bank that spent seven years unable to grow has spent fifteen months deploying a balance sheet into markets financing, commercial relationships, and an investment bank taking measurable share, paid for it with a ratio rather than with dollars, and is now at the point where th...
Read Article ›At 16x guided 2026 adjusted operating profit and 34x the guided cash floor, with clean margin lower than a year ago and the 2027 step resting on suppliers, Embraer's equity is fully valued — a franchise worth owning at a price the market is no longer offering.
Read Article ›At eleven times forward earnings against a mid-thirties return on equity and a client cohort deepening at 34% per relationship, the risk-reward is skewed to the upside, and the stock is worth owning even after the run.
Read Article ›The market has assigned MercadoLibre the multiple of a business whose profitability has been permanently reset, while the disclosures show a company deliberately buying engagement, logistics density and a 20%-plus-margin loan book with money it could stop spending in a quarter...
Read Article ›At roughly 25x next year's consensus earnings for a business converting three-quarters of net income to cash and taking share on both sides of the Atlantic, Eli Lilly is mispriced to the upside — and the risk-reward has not turned, it has merely become less generous than it wa...
Read Article ›The debate isn't whether URBN is a good business—it's whether the crowd re-rates it before the numbers force the issue. I think the setup into holiday, backed by buybacks and a conservatively built margin plan, tilts that resolution in shareholders' favor.
Read Article ›